Comment on ’Effectiveness of 190 μg Fluocinolone Acetonide versus 700 μg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis’ [Response to Letter]

Javier Zarranz-Ventura,1 Joshua O Mali2 1Institut Clínic d’Oftalmología (ICOF), Hospital Clinic, Barcelona, Spain; 2The Eye Associates, Sarasota, FL, USACorrespondence: Javier Zarranz-VenturaInstitut Clínic d’Oftalmología (ICOF), Hospit...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zarranz-Ventura J, Mali JO
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2020
Materias:
Acceso en línea:https://doaj.org/article/cb30bb0aa04343109604b98c82bcae47
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Javier Zarranz-Ventura,1 Joshua O Mali2 1Institut Clínic d’Oftalmología (ICOF), Hospital Clinic, Barcelona, Spain; 2The Eye Associates, Sarasota, FL, USACorrespondence: Javier Zarranz-VenturaInstitut Clínic d’Oftalmología (ICOF), Hospital Clinic, Barcelona, SpainTel +34 932 279 391Email jzarranz@hotmail.com With interest, we read the letter to the Editor regarding the Effectiveness of 190 μg fluocinolone acetonide versus 700 μg dexamethasone intravitreal implants in diabetic macular edema using the area-under-the-curve method: The CONSTANT analysis by Stewart and Taylor published in Clinical Ophthalmology. The key concerns raised by the authors relate to the design deficiencies of the MEAD studies1 and highlight two specific issues – the six month dosing of the dexamethasone implant and the potentially delayed removal of cataracts.   View the original paper by Zarranz-Ventura and Mali   This is in response to the Letter to the Editor